USA flag logo/image

An Official Website of the United States Government

Capsid assembly inhibitors for the treatment of AIDS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75886
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
AI064090
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. 300 George St, Ste 801 New Haven, CT 06511 0665
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Capsid assembly inhibitors for the treatment of AIDS
Agency: HHS
Contract: 1R43AI064090-01
Award Amount: $597,665.00
 

Abstract:

DESCRIPTION (provided by applicant): Current HIV-1 therapy suffers from inadequate viral load suppression due to poor compliance, resistance, and interactions with other drugs and can lead to spread of drug-resistant strains. The current drug cocktails need to include inhibitors of viral components that are likely to slow resistance development. One such target is the HIV-1 capsid, an essential viral protein, where mutations are lethal or lead to production of non-infectious viral particles. Discovery of compounds that affect the assembly of structural proteins is challenging due to lack of a biochemical assay that can be adopted for high throughput screening of large compound libraries. We have recently reported an inhibitor of capsid assembly that reduced viral infectivity by ca. 95%. Cap-1 (ACH-1033940) was identified by combining the Computational Chemistry, NMR, and Virology efforts. Phase I of this proposal includes identification of a potent capsid assembly inhibitor (EC50 <10 mu/M, therapeutic index >10) as well as discovery of additional potent and drug like capsid ligands. The Phase I goal will be accomplished using a dual approach of rationally designing and synthesizing focused libraries of ACH-0133940 analogs and Virtual Screening of proprietary and commercial compound libraries to identify novel capsid ligands. The potential ligands will be screened for capsid binding by NMR and for inhibition of HIV by in vitro antiviral assays. Resistance induction studies will be carried out to confirm that inhibition of HIV infectivity is due to the inhibition of capsid assembly. Phase II of the project will entail further lead optimization and identification of development candidate(s).

Principal Investigator:

Atul Agarwal
2037525491
AAGARWAL@ACHILLION.COM

Business Contact:


2036247000
Small Business Information at Submission:

Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. 300 George St, Ste 801 New Haven, CT 06511

EIN/Tax ID: 522113479
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No